Compare DLX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLX | OCS |
|---|---|---|
| Founded | 1915 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.6M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | DLX | OCS |
|---|---|---|
| Price | $22.22 | $20.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $23.00 | ★ $39.80 |
| AVG Volume (30 Days) | ★ 277.4K | 93.1K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | ★ 47.66 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $2,118,526,000.00 | $991,999.00 |
| Revenue This Year | $0.58 | $35.00 |
| Revenue Next Year | $1.08 | $874.12 |
| P/E Ratio | $12.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.61 | $14.00 |
| 52 Week High | $24.30 | $23.08 |
| Indicator | DLX | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 57.55 |
| Support Level | $20.80 | $18.64 |
| Resistance Level | $21.08 | $21.86 |
| Average True Range (ATR) | 0.57 | 0.62 |
| MACD | 0.19 | 0.18 |
| Stochastic Oscillator | 93.33 | 60.87 |
Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.